What Quest Diagnostics's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Quest Diagnostics filed its latest 10-Q with the SEC on Oct 23, 2026. It discusses AI investment, debt refinancing and digital transformation.
Public (DGX)Hospitals and Health Care10,000+ employeesquestdiagnostics.comLinkedIn
Get Quest Diagnostics' live signals in Claude or ChatGPT, or by API
What changed at Quest Diagnostics this week? Use Autobound signals for questdiagnostics.com.- Filed
- Oct 23, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 13
Source: Autobound Signal API · 69 signals tracked for Quest Diagnostics · updated
10-Q · latest 10
What Quest Diagnostics's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
Quest Diagnostics advances multi-year Project Nova to modernize Order-to-Cash business processes
SG&A expense growth in Q3 2026 was driven in part by spending on Project Nova, a multi-year project to modernize Order-to-Cash processes.
Order-to-Cash
Quest Diagnostics and Corewell Health completed their transaction in January 2026 to form a new Michigan entity owned 51% by Quest and 49% by Corewell Health, operating until a new laboratory opens in 2027.
51%
equity ownership of the newly formed entity
Quest Diagnostics completed $500 million offering of 5.00% senior notes due June 2036
In May 2026, Quest Diagnostics completed a senior notes offering consisting of $500 million aggregate principal amount of 5.00% senior notes due June 2036.
$500M
aggregate principal amount of 5.00% senior notes offering due June 2036
5%
interest rate on 2036 senior notes
Fresenius Medical Care and Corewell Health partnerships drive 9.5% DIS volume increase
Relationships with Corewell Health and increased laboratory testing at dialysis clinics owned by Fresenius Medical Care in the United States contributed 9.5% of DIS volume growth.
9.5%
volume increase attributable to Corewell Health and Fresenius Medical Care testing
Quest Diagnostics deploys AI and automation across value chain targeting 3% annual savings
Under the Invigorate program, Quest Diagnostics is deploying artificial intelligence and automation across its entire value chain to improve productivity and quality.
3%
annual cost savings and productivity improvements target
automationartificial intelligence
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Quest Diagnostics and Corewell Health finalized their entity with Quest owning 51% and Corewell Health owning 49% to perform lab testing in Michigan, operating from existing sites until a new facility opens in 2027.
51%
equity ownership held by Quest Diagnostics in the newly formed entity
Testing expansion at Fresenius Medical Care dialysis clinics boosted Q2 2026 DIS volume
Increased laboratory testing at Fresenius Medical Care dialysis clinics, alongside the Corewell Health relationship, drove approximately 9% of organic volume growth in Q2 2026.
9%
organic volume growth driven by Corewell Health and Fresenius Medical Care relationships
Quest Diagnostics completes $500M 2036 Senior Notes offering to refinance maturing debt
In May 2026, Quest Diagnostics completed an offering of $500 million of 5.00% senior notes due June 2036 at an original issue discount of $6 million.
$500M
aggregate principal amount of 5.00% senior notes due June 2036 issued to refinance maturing debt
5%
senior notes interest rate
Quest Diagnostics targets 3% annual cost savings via multi-year Invigorate productivity program
Quest Diagnostics is executing its multi-year Invigorate program targeting 3% annual cost savings and productivity gains across the value chain, including automation and artificial intelligence implementations.
3%
annual cost savings and productivity improvements target
automationartificial intelligence
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 4 signals
Completed 51%-owned Michigan laboratory testing joint venture with Corewell Health in January 2026
Quest Diagnostics completed a transaction in January 2026 to form a new Michigan entity owned 51% by Quest and 49% by Corewell Health, operating existing sites until a new lab opens in 2027.
51%
equity ownership shared by Quest Diagnostics in the newly formed entity
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Quest Diagnostics earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Full-year revenue guidance raised to $12.065B to $12.105B rangeFull-year 2026 revenue guidance was increased and narrowed to $12.065 billion to $12.105 billion, representing 9.3% to 9.7% annual growth. Adjusted EPS expectations were also boosted to $11.25 to $11.35, backed by expected operating cash flows of approximately $1.9 billion. | |
| Deploying AI and automated aliquoting to drive lab productivityAutomation and artificial intelligence solutions are being rolled out across laboratory operations, including an AI tool in the Clifton, New Jersey lab to scan dialysis water testing samples. Automated specimen aliquoting has expanded to 10 labs, including 3 drug monitoring facilities, reducing manual touchpoints and driving productivity gains under the Invigorate program. | |
| Revenues reach $3.1B up 10% with operating margin expandingConsolidated third-quarter revenues reached $3.1 billion, rising 10% year-over-year with organic revenue up 10.1%. Adjusted operating income grew to $517 million or 16.7% of revenues, demonstrating operational leverage and expanding margins that provide healthy operating budget for technology and lab solutions. | |
| Capital expenditures guidance pegged at $550 million for 2026Annual capital expenditures are targeted at approximately $550 million for 2026 out of $1.9 billion in expected operating cash flow. This planned capital expenditure supports ongoing lab enhancements, facility upgrades, and equipment deployments. | |
| Advancing Project Nova build phase for Epic lab deploymentProject Nova has transitioned from design to the solutions build phase with plans to deploy Epic Systems software in the first lab by fall 2027. The project carries an estimated $0.25 full-year EPS impact for 2026, with 70% of expenses incurred during the second half, heavily weighted toward Q4. | |
| Consumer health revenue projected to grow over 30% in 2026The direct-to-consumer health channel is outpacing overall growth, with annual expansion projected to exceed 30% for the full year. Driven by questhealth.com and retail consumer wellness initiatives, the segment offers margin-accretive profiles due to dense requisitions and absent payer concessions. |
Signal API · MCP
Track Quest Diagnostics with the Signal API
One POST /v1/companies/enrich call with questdiagnostics.com returns Quest Diagnostics 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"questdiagnostics.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Quest Diagnostics 10-Q
When did Quest Diagnostics file its latest 10-Q?
What did Quest Diagnostics disclose in its latest 10-Q?
What did Quest Diagnostics say on its recent earnings calls?
Where can I read Quest Diagnostics's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .